Request Study Information

After you submit your request, a staff member will contact you.There’s no obligation and our team is here to help you decide on a study that’s best for you.

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

This Phase II trial tests the safety and potential benefits of AZD6234 for people with overweight or obesity and Type 2 Diabetes already using a GLP-1 receptor agonist. The goal is to see whether AZD6234 can support better weight and blood sugar control. Participants will continue their current treatment while also receiving the study drug or a placebo.

Eligibility:
• Ages 18–75
• Diagnosed with Type 2 Diabetes
• Currently using a GLP-1 medication and not using insulin

Enter Your Information

(All fields are required)

Study Request Form (specific)

Name(Required)
Date of Birth(Required)
Race(Required)
Select one or more options that best describe you. This information can help ensure that all populations are represented in research.

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from ECIR and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at [email protected]. For full details, refer to ECIR’s privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.